Where is the next explosion in the gene sequencing market? China has announced the launch of a precision medical program, which is regarded as an important means of accurately combating tumors. The liquid biopsy technology of tumor genes will surely become the next huge market opportunity.
Tumor gene "liquid biopsy": "target" for cancer precision medicine
Non-invasive testing is the first killer application for gene sequencing, and it is known for screening for fetal Down syndrome (also known as "fetal 21-trisomy syndrome" or congenital). The data show that in the past three years, a total of 200,000 pregnant women in China have received prenatal genetic testing. On January 16, 2015, the National Health and Family Planning Commission released the first list of 108 pilot medical institutions for non-invasive genetic testing. According to industry analysts, China's non-invasive production inspection will create a market of about 10 billion.
So, where is the next explosion in the gene sequencing market? China has announced the launch of a precision medical program, which is regarded as an important means of accurately combating tumors, so the liquid biopsy technology of tumor genes will surely become the next huge market opportunity. . In the details of the White House's official website released on February 8 this year, one of the four major initiatives of the cancer treatment program is that the United States will use "liquid biopsy" plasma to develop new methods to assess treatment response and resist possible drug resistance. So, what is the technology of “liquid biopsy†and why is it so valued?
A liquid biopsy of a tumor gene is a technique for detecting ctDNA (a small fragment tumor gene released from death on a dead tumor cell) in circulating blood of a human body. It can detect whole body tumor information by non-invasive blood sampling in vitro, which is very suitable for early diagnosis and precise medical treatment of cancer. Traditional methods of tumor detection have many limitations: for example, tissue biopsy requires surgery to take a slice from a tumor, which causes great pain to the patient and cannot be performed frequently. It can only detect a single organ, and its limitations are very large, which is not suitable for routine physical examination. Liquid biopsy allows doctors to monitor the development of the tumor frequently, and by blood drawing, it is possible to quickly determine whether a treatment is appropriate for the patient. If the treatment plan is not effective, you can give up immediately, avoid the patient suffering from side effects, and let the doctor try the alternative as soon as possible.
Accurate medical care is a customized medical model based on personal genomic information to design the best treatment for patients to achieve maximum therapeutic effect and minimize side effects. The key to precision medicine to be personalized, efficient and preventive is screening and diagnosis. Therefore, the development of detection and diagnosis technologies such as gene sequencing is the key. As Obama said: "We have 'typed our genetic code' with cancer and become a viable standard. We decide that the dose of the drug will be as convenient as measuring our body temperature - this is the precision medicine for us. Hope. "Immunotherapy, targeted therapy, etc., are all ways in which the medical profession is more precise in treating cancer. They provide new shells for humans to overcome cancer, but all shells need an scope analysis before accurately hitting the target. Individual tumor gene mutations, otherwise the drug cannot be accurately selected. "Liquid biopsy" is the sight and radar of cancer "precise medical". This is why Obama’s “precise medical†program values ​​it so much.
"Precision medical care": the huge demand in China's cancer market
Cancer is the most deadly disease in the world. Thanks to breakthroughs in DNA sequencing and the Cancer Genome Atlas project, understanding of the molecular changes that trigger cancer has deepened, and new understandings of oncogene information have affected the drug and antibody design process. International pharmaceutical giants and venture capitalists have long been targeting this hot area. According to Illumina's data, the global NGS (second-generation gene sequencing) application market is expected to be 20 billion US dollars. Drug development and clinical application are the fastest growing areas, with a growth rate of more than 15%. Tumor diagnosis and personalized medicine are the most There are areas of application prospects with a market size of $12 billion.
Similarly, this is also a huge market in China. Statistics show that there are about 3.5 million new cases of tumors in China every year. Taking the average life expectancy of 80 years as an example, the risk of cancer in Chinese people is as high as 22%; 80% of tumors occur after 50 years of age. These sets of data indicate that tumor diseases are a high incidence in China, and middle-aged and elderly people are high-risk populations of cancer diseases. This has to be taken seriously by everyone. Cancer causes pain to many patients, and its treatment process is often toxic and harmful to the body. It causes many families to become poor due to illness. The difficult treatment process also aggravates the fear of patients and their families, which makes cancer more than just A medical problem has also become a serious social problem.
However, at present, the detection technology of most domestic gene sequencing companies is not complete enough in terms of applicability, and related genetic testing products and services are very limited. Early screening and guiding the accurate use of drugs (especially targeted drugs) in cancer patients is the most urgent two needs in the current market, but the existing products and services can not meet these two needs very well. This is a There are markets that have huge demand and have not yet been met.
Today, Chemical Products play an important role in our life, with the development of science and technology, at first, only by soda ash, chemical products and other inorganic sulfate product and plant extracts, organic products, to develop a hybrid multiple industries and variety of industries, mainly and plastic chemical industry, synthetic fiber, oil, rubber, pharmaceutical, dye industry, etc. They are all departments that use chemical reactions to change the structure, composition, morphology and other chemical products. Such as: inorganic acid, alkali, salt, rare elements, synthetic fiber, plastic, synthetic rubber, dye, paint, chemical fertilizer, pesticides, etc.
Our main Chemical Products are:ETHYL 2-CHLOROBENZOATE,Allylthiourea,Chloro-2-Methylpropane,Sodium 4-propan-2-ylbenzenesulfonate,POLY(ISOBUTYL METHACRYLATE),Resin Acids,Decaglyceryl Monooleate,Heptafluorobutanol,Aluminum Acetate,Allyl Methacrylate,2-Bromopentane,Sulfuryl Chloride.
We are a biotechnology company in pharmaceutical raw materials production research and development, We had passed FDA certificate and ISO 9001 .we have enough experience, our company has the GMP production workshop and standard plant extraction equipment dozens of Taiwan, starting in 2012, in response to increase export of national policy, our company started drug raw materials exports, at present, the company has 50 people the size of the foreign trade sales team, Annual sales are $30 million. We can produce high quality of Vitamin Products, at the same time, we are factory price of Vitamin K2 Powder, extracted by professional production equipment, can produce supply Vitamin And Enzyme,
Tributyl Phosphate, TBP,ANTIFOAMT, AURORA KA-1641, BUTYL PHOSPHATE
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com